HSBC ups Ranbaxy to overweight on generic Lipitor announcement
Reuters: Mumbai, Feb 25 2013, 10:28 IST
HSBC raised its rating on shares of Ranbaxy Laboratories Ltd to 'overweight' from 'underweight' after the Indian drugmaker said it would resume production of a generic version of cholesterol fighter Lipitor for sale in the United States.
HSBC added other factors behind its upgrade were share valuations after a recent correction, as well as the near-term catalysts such as the launch of additional generic drugs and the probability of a recovery in U.S. sales.
Ranbaxy shares were up 3.2 percent as of 0356 GMT.
Stocks More on Ranbaxy Laboratories
Previous Story Virat Kohli: Few players can score 200 with M S Dhoni's strike-rate Next Story Hyderabad blasts: Seven-year-old with Down's Syndrome among many injured
Reader's Comments| Post a Comment
Be the first to comment.
